In addition, it was found that in NAFLD, osteoprotegerin could regulate liver lipid metabolism by targeting the ERK/PPARγ/CD36 pathway, and hypertension could be regulated by the ERK/PPARγ signal pathway in cardiovascular disease [59]. Here, TNFRSF11B is linked to metabolic dysfunction-associated steatotic liver disease.